Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.53 +0.01 (+0.02%)
Streaming Delayed Price Updated: 1:32 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
35 36 Next >
News headline image
3 Fierce Stocks That Are Screaming Buys in December ↗
Here are three winners in the making. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗
The company has already made plenty of investors happy. 
Via The Motley Fool
News headline image
Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023 ↗
These top players are ripe for recovery -- and long-term growth. 
Via The Motley Fool
News headline image
3 Growth Stocks That Are Too Cheap to Ignore ↗
Overlooking these stocks in the current market could be a mistake. 
Via The Motley Fool
News headline image
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing ↗
Here's how Ark Invest's top holdings have performed in 2022. 
Via Investor's Business Daily
What 5 Analyst Ratings Have To Say About CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
Why Shares of CRISPR Therapeutics Dropped 19.9% in October ↗
Several factors weighed on the gene-editing biotech stocks last month. 
Via The Motley Fool
News headline image
Where CRISPR Therapeutics Stands With Analysts ↗
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
2 Stocks Near 52-Week Highs That Could Climb Higher ↗
This pair of stocks are bucking the trend and they could climb even higher. 
Via The Motley Fool
News headline image
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead ↗
The ARK Invest founder might regret trimming her position in this biotech stock. 
Via The Motley Fool
News headline image
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
News headline image
Where Will Editas Medicine Be in 1 Year? ↗
The company could continue lagging the market for a while. 
Via The Motley Fool
News headline image
2 Growth Stocks That Could Double in 2023 ↗
Both are lagging the market this year. 
Via The Motley Fool
News headline image
Crispr Therapeutics Stock: Bull vs. Bear ↗
Crispr shares have fallen about 20% so far this year. 
Via The Motley Fool
News headline image
5 Top Stocks to Buy Before 2023 ↗
These stocks have what it takes to win over time. 
Via The Motley Fool
News headline image
Vertex Pharmaceuticals: Buy at the High? ↗
Vertex is submitting a potential blockbuster to regulators this month. 
Via The Motley Fool
News headline image
Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade ↗
These top stocks could be wise additions to a well-rounded investment portfolio. 
Via The Motley Fool
News headline image
3 Top Healthcare Stocks Defying the Bear Market ↗
These healthcare companies haven't been slowed by macroeconomic conditions. 
Via The Motley Fool
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
3 Healthcare Stocks That Could Go Parabolic ↗
These beaten-down stocks are ready for a rebound. 
Via The Motley Fool
News headline image
Got $1,000? 2 Smart Stocks to Consider Buying Right Now ↗
Don't overlook these major healthcare names on your next stock-buying spree. 
Via The Motley Fool
News headline image
2 Biotech Stocks That Could Make You Richer ↗
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
News headline image
3 Top Healthcare Stocks to Buy for November ↗
Catalysts lie ahead for these promising stocks. 
Via The Motley Fool
News headline image
What 8 Analyst Ratings Have To Say About CRISPR Therapeutics ↗
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings: 
Via Benzinga
News headline image
Expert Ratings for CRISPR Therapeutics ↗
Over the past 3 months, 8 analysts have published their opinion on CRISPR Therapeutics (NASDAQ:CRSP) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Better Buy: CRISPR Therapeutics vs. Bluebird Bio ↗
These two companies have performed almost equally poorly on the stock market in the past year. 
Via The Motley Fool
News headline image
2 Monster Stocks to Buy Without Any Hesitation ↗
These stocks are crushing the bear market. 
Via The Motley Fool
News headline image
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.48% on an annualized basis producing an average annual return of 21.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
S&P 500 Biotech Giant Vertex Leads 5 Stocks Showing Strength ↗
Vertex and LNG play Cheniere Energy are setting up bullishly. 
Via Investor's Business Daily
News headline image
The Top 5 Stocks Cathie Wood Bought and Sold This Week ↗
Cathie Wood's flagship ETF, the ARK Innovation ETF, hit a five-year and 52-week low this week, casting doubts on the investment manager. 
Via InvestorPlace
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.